XML 19 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 71,143,778 $ 250,728,118
Short-term investments 330,170,940 160,914,935
Accounts receivable 5,466,850 18,559,967
Accounts receivable from affiliated entities 2,565,194 503,782
Prepaid expenses and other current assets 38,836,991 40,357,456
Prepaid expenses and other current assets from affiliated entities 261,192 106,432
Total current assets 448,444,945 471,170,690
Fixed assets, net 17,453,206 11,348,144
Investments in affiliated entity 3,906,796 4,460,366
Investment in Geneos 0 434,387
Intangible assets, net 2,626,355 3,146,770
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 11,571,026 12,741,296
Other assets 1,425,794 25,957,448
Total assets 495,941,493 539,772,472
Current liabilities:    
Accounts payable and accrued expenses 47,644,530 21,203,808
Accounts payable and accrued expenses due to affiliated entities 548,032 642,969
Accrued clinical trial expenses 10,326,266 9,950,345
Deferred revenue 21,628 46,628
Operating lease liability 2,603,956 2,329,394
Grant funding liability 4,559,721 7,474,310
Grant funding liability from affiliated entities 37,500 58,500
Total current liabilities 65,741,633 41,705,954
Deferred revenue, net of current portion 64,361 79,214
Operating lease liability, net of current portion 15,459,559 18,063,515
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 0 37,500
Other liabilities 14,826 57,663
Total liabilities 96,272,072 78,631,714
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2021 and 2020 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2021 and 2020, issued and outstanding: 217,382,887 at December 31, 2021 and 186,851,493 at December 31, 2020 217,382 186,851
Additional paid-in capital 1,609,589,797 1,367,406,869
Accumulated deficit (1,209,855,522) (906,196,812)
Accumulated other comprehensive income (loss) (282,236) (256,150)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 399,669,421 461,140,758
Total liabilities and stockholders’ equity 495,941,493 539,772,472
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 14,959,647 14,139,988
Convertible Bonds    
Current liabilities:    
Convertible debt $ 0 $ 4,515,834